Investigation into the frequency of anti-immunoglobulin autoantibodies in humans that bind to GSK2862277 (a variable heavy chain domain antibody targeting human TNFR1) and the potential for dAb:autoantibody complexes to activate TNFR1 signalling.

Study code
CBR109

Lead researcher
Dr Andrew Bayliffe

Study type
Samples and data

Institution or company
GlaxoSmithKline

Researcher type
Commercial

Speciality area
Infection

Recruitment Site
Cambridge

Summary

The aim of the study is to explore the function of human anti-immunogloblin autoantibody responses and why they are present in humans. 

Participation: 4000 serum samples from the Cambridge BioResource volunteers were provided for this study.

Organisation: This study is organised by Dr Andrew Bayliffe from GlaxoSmithKline.